BioNTech Other Liab vs Other Assets Analysis
0A3M Stock | USD 110.25 4.06 3.55% |
BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Other Liab and its Other Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Other Liab vs Other Assets
Other Liab vs Other Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Other Liab account and Other Assets. At this time, the significance of the direction appears to have weak relationship.
The correlation between BioNTech's Other Liab and Other Assets is 0.3. Overlapping area represents the amount of variation of Other Liab that can explain the historical movement of Other Assets in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Other Liab and Other Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Liab of BioNTech SE are associated (or correlated) with its Other Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Assets has no effect on the direction of Other Liab i.e., BioNTech's Other Liab and Other Assets go up and down completely randomly.
Correlation Coefficient | 0.3 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Other Liab
Other Assets
Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. The value of Tax Provision is estimated to slide to about 243 M. The value of Selling General Administrative is expected to slide to about 293.8 M
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 15.1B | 12.8B | 3.2B | 5.8B | Total Revenue | 19.0B | 17.3B | 3.8B | 7.5B |
BioNTech fundamental ratios Correlations
Click cells to compare fundamentals
BioNTech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Not Found
BioNTech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Current Liab | 105.6M | 494.6M | 3.2B | 1.6B | 540.3M | 964.9M | |
Total Current Liabilities | 138.1M | 606M | 3.5B | 3.0B | 2.1B | 1.5B | |
Other Liab | 205.6M | 97.1M | 109.8M | 283.9M | 326.5M | 200.3M | |
Net Tangible Assets | 179.6M | 406.5M | 1.2B | 11.7B | 13.5B | 14.1B | |
Retained Earnings | (424.8M) | (409.6M) | 9.9B | 18.8B | 19.8B | 20.8B | |
Accounts Payable | 20.5M | 102.3M | 160M | 204.1M | 354M | 371.7M | |
Other Assets | 2.4M | 168.2M | 22.2M | 249.2M | 286.6M | 300.9M | |
Net Receivables | 20.2M | 166.4M | 12.4B | 7.1B | 2.2B | 3.4B | |
Inventory | 12.1M | 64.1M | 502.5M | 439.6M | 357.7M | 217.8M | |
Other Current Assets | 7.0M | 89M | 113.4M | 271.9M | 280.9M | 294.9M | |
Other Stockholder Equity | 318.6M | 691.5M | 1.5B | 1.8B | 2.0B | 2.1B | |
Total Current Assets | 560.2M | 1.7B | 15.1B | 21.9B | 19.5B | 20.5B | |
Property Plant Equipment | 116.0M | 148.1M | 326M | 520.4M | 598.5M | 628.4M | |
Total Assets | 797.6M | 2.3B | 15.8B | 23.3B | 23.0B | 12.1B | |
Total Stockholder Equity | 493.5M | 1.4B | 11.9B | 20.1B | 20.2B | 21.3B | |
Cash | 519.1M | 1.2B | 1.7B | 13.9B | 11.7B | 12.2B | |
Non Current Assets Total | 237.5M | 651.7M | 758.5M | 1.4B | 3.5B | 3.7B | |
Non Currrent Assets Other | 2K | 1.0M | 800K | 6.5M | 83.4M | 87.6M | |
Good Will | 3.0M | 53.7M | 57.8M | 61.2M | 362.5M | 380.6M | |
Common Stock Shares Outstanding | 226.8M | 241.5M | 242.5M | 243.2M | 237.7M | 260.6M | |
Short Term Investments | 1.7M | 137.2M | 381.6M | 189.4M | 4.9B | 5.1B | |
Non Current Liabilities Total | 166.0M | 340.8M | 455.5M | 272.9M | 689.9M | 400.6M | |
Total Liab | 304.2M | 946.8M | 3.9B | 3.2B | 2.8B | 2.1B | |
Net Invested Capital | 493.5M | 1.4B | 12.2B | 20.3B | 20.5B | 21.5B | |
Capital Stock | 232.3M | 246.3M | 246.3M | 248.6M | 285.9M | 259.5M | |
Net Working Capital | 422.0M | 1.1B | 11.6B | 19.0B | 17.5B | 9.1B | |
Intangible Assets | 86.5M | 109.8M | 144.6M | 158.5M | 804.1M | 844.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.